Hydroxychloroquine Prophylaxis for COVID-19

Main Article Content

David D. Busath, MD


It is common in medicine that simple, inexpensive remedies are held hostage to medical prejudice, financial or political interest, and legal precedent. The purpose of this review is to take the point of view of the victims of COVID-19 and address whether scientific information, including randomized-control trials, can answer whether the hydroxychloroquine should be dispensed for those testing positive and their immediate recent contacts at the point of testing. Although the FDA in the United States is yet to be convinced, the demonstration of positive effects in clinical trials cannot be ignored and there is a large amount of information in the pipeline (published pre-prints and registered clinical trials) that could tip the scales towards making the drug readily available for early disease and contact-prophylactic usage to reduce peak symptoms, symptom duration, contagiousness, hospitalizations and mortality. 

Article Details

How to Cite
BUSATH, David D.. Hydroxychloroquine Prophylaxis for COVID-19. Medical Research Archives, [S.l.], v. 8, n. 10, oct. 2020. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2263>. Date accessed: 27 nov. 2020. doi: https://doi.org/10.18103/mra.v8i10.2263.
Research Articles


1. Klepser ME, Adams AJ. 2018. Pharmacy-based management of influenza: lessons learned from research. The International journal of pharmacy practice 26:573-8
2. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, et al. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283:1016-24
3. Hurt AC, Kelly H. 2016. Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza. Emerg Infect Dis 22:949-55
4. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, et al. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza - Randomized controlled trials for prevention and treatment. Jama-Journal of the American Medical Association 282:1240-6
5. Wang M, Cao R, Zhang L, Yang X, Liu J, et al. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269-71
6. Touret F, Gilles M, Barral K, Nougairede A, van Helden J, et al. 2020. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep 10:13093
7. Weston S, Coleman CM, Haupt R, Logue J, Matthews K, et al. 2020. Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. J Virol
8. Liu J, Cao RY, Xu MY, Wang X, Zhang HY, et al. 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 6:1-4
9. Huang M, Tang T, Pang P, Li M, Ma R, et al. 2020. Treating COVID-19 with Chloroquine. J Mol Cell Biol 12:322-5
10. Gautret P, Lagier JC, Parola P, Hoang V, Meddeb L, et al. 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents 56
11. Sánchez-Álvarez JE, Fontán MP, Martín CJ, Pelícano MB, Reina CJC, et al. 2020. Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). Nefrología (English Edition) 40:272-8
12. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, et al. 2020. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 35:101738
13. Okour M, Al-Kofahi M, Austin D. 2020. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome. J Pharmacokinet Pharmacodyn 47:187-8
14. Yu B, Li C, Chen P, Zhou N, Wang L, et al. 2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci
15. Huang M, Li M, Xiao F, Pang P, Liang J, et al. 2020. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. National Science Review 7:1428-36
16. Ayerbe L, Risco C, Ayis S. 2020. The association between treatment with heparin and survival in patients with Covid-19. J Thromb Thrombolysis 50:298-301
17. Wonner M, Andreis NR-d, Sarrazin E, Lacrosse P, Lardenois T, et al. 2020. Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19. Asian Journal of Medicine and Health:45-55
18. Chen J, Liu D, Liu L, Liu P, Xu Q, et al. 2020. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban 49:215-9
19. Tang Wea. 2020. Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial. medRxiv Preprint
20. Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, et al. 2020. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. Med 1:1-14
21. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, et al. 2020. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 382:2411-8
22. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, et al. 2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA 323:2493-502
23. Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, et al. 2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 369:m1844
24. Kupferschmidt K. 2020. U.K. megatrial outshines other drug studies. Science 369:124-5
25. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. 2020. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open 3:e208857
26. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, et al. 2020. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 5:1036-41
27. Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, et al. 2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc 9:e017144
28. Bessiere F, Roccia H, Deliniere A, Charriere R, Chevalier P, et al. 2020. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. JAMA Cardiol 5:1067-9
29. Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, et al. 2020. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol
30. Bakhshaliyev N, Uluganyan M, Enhos A, Karacop E, Ozdemir R. 2020. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. J Electrocardiol 62:59-64
31. Prodromos CC, Rumschlag T, Perchyk T. 2020. Hydroxychloroquine is protective to the heart, not harmful: a systematic review. New Microbes New Infect 37:100747
32. Mitja O, Corbacho-Monne M, Ubals M, Tebe C, Penafiel J, et al. 2020. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. Clin Infect Dis In press
33. Lee SH, Son H, Peck KR. 2020. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents 55:105988
34. Zhong J, Shen G, Yang H, Huang A, Chen X, et al. 2020. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. The Lancet Rheumatology 2:e557-e64
35. Meo SA, Klonoff DC, Akram J. 2020. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci 24:4539-47
36. Romão VC, Cruz-Machado AR, Fonseca JE. 2020. Mounting data indicate that antimalarials do not prevent mild or severe COVID-19 in rheumatic patients. Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al. Ann Rheum Dis
37. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, et al. 2020. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584:430-6
38. Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, et al. 2020. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol
39. Ferreira A, Oliveira ESA, Bettencourt P. 2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J Med Virol
40. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, et al. 2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 383:517-25
41. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, et al. 2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. Ann Intern Med
42. Pirnay G, Dantier B, Tourid W, Terkemani A, Bachot F, et al. 2020. Effet bénéfique de l’association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d’une étude observationnelle. Le Pharmacien Hospitalier et Clinicien
43. Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, et al. 2020. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis:101791
44. Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, et al. 2020. Risk Factors for Mortality in Patients with COVID-19 in New York City. J Gen Intern Med
45. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, et al. 2020. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 97:396-403
46. Hong KS, Jang JG, Hur J, Lee JH, Kim HN, et al. 2020. Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication. Infect Chemother
47. d'Arminio Monforte A, Tavelli A, Bai F, Marchetti G, Cozzi-Lepri A. 2020. Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal? Int J Infect Dis 99:75-6
48. Davido B, Boussaid G, Vaugier I, Lansaman T, Bouchand F, et al. 2020. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. Int J Antimicrob Agents 56:106129
49. Yu B, Li C, Chen P, Li J, Jiang H, Wang DW. 2020. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. Sci China Life Sci
50. Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, et al. 2020. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov
51. Dubernet A, Larsen K, Masse L, Allyn J, Foch E, et al. 2020. A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Reunion Island. J Glob Antimicrob Resist 23:1-3
52. Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, et al. 2020. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. Int J Antimicrob Agents 56:106144
53. Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, et al. 2020. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. Eur J Intern Med In press.
54. Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, et al. 2020. Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran. Tohoku J Exp Med 252:73-84
55. Bruno Heberto A, Corona Juan Carlos P, Rubio Jose Antonio C, Perez Patricia P, Rasgado Enrique T, et al. 2020. Implications of Myocardial Injury in Mexican Hospitalized Patients with Coronavirus Disease 2019 (Covid-19). Int J Cardiol Heart Vasc 30:100638
56. Lauriola M, Pani A, Ippoliti G, Mortara A, Milighetti S, et al. 2020. Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients. Clin Transl Sci
57. Giacomelli A, Pagani G, Ridolfo AL, Oreni L, Conti F, et al. 2020. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. J Med Virol
58. Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, et al. 2020. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov
59. Kelly M, O'Connor R, Townsend L, Coghlan M, Relihan E, et al. 2020. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. Br J Clin Pharmacol
60. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, et al. 2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med
61. Lopez A, Duclos G, Pastene B, Bezulier K, Guilhaumou R, et al. 2020. Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results. Int J Antimicrob Agents:106136
62. Lecronier M, Beurton A, Burrel S, Haudebourg L, Deleris R, et al. 2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. Crit Care 24:418
63. Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. 2020. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Intern Med
64. Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. 2020. Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. Ann Intern Med
65. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. 2020. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
66. Park SJ, Yu KM, Kim YI, Kim SM, Kim EH, et al. 2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. mBio 11
67. Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, et al. 2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature
68. Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, et al. 2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J 34:6027-37
69. McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, et al. 2020. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med
70. Kashour T, Tleyjeh IM. 2020. It is time to drop hydroxychloroquine from our COVID-19 armamentarium. Medical Hypotheses 144:110198
71. Elbazidi H, Erraih O. 2020. Pandemic and social changes, political fate. New Microbes New Infect:100749

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.